Details of the Drug Reposition

General Information of This Drug (ID: DMCFTTN)

• Drug Name: Runcaciguat (DMCFTTN)
• Synonyms: Runcaciguat; 1402936-61-1; Runcaciguat [INN]; 5EZ01YDT5S; UNII-5EZ01YDT5S; (3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; CHEMBL4650322; SCHEMBL20075857; GTPL12359; AKOS040742586; BAY1101042; BAY 1101042; BAY-1101042; compound 45 [PMID: 33872507]; AC-37098; MS-29070; HY-109136; CS-0086784; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; XZ7
• Drug Type: Small molecule

Information on Drug Reposition of This Drug

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-proliferative diabetic retinopathy	DISPMG3Z	9B71.00	Phase 2	[1]
Chronic kidney disease	DISW82R7	GB61	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT04722991) A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04507061) A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Individually Titrated Oral Doses of Runcaciguat in Subjects With Clinical Diagnosis of Chronic Kidney Disease With Diabetes and/or Hypertension and at Least One Cardiovascular Comorbidity. U.S.National Institutes of Health.